UCH-L1/PGP9.5 Antibody [Alexa Fluor™ Plus 555]

• Reactivity: Hu, Mu, Rt
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor Plus 555

UCH-L1/PGP9.5 Antibody [Alexa Fluor™ Plus 555] Summary

• Specificity: Detects human, mouse, and rat UCH-L1/PGP9.5 in direct ELISAs and Western blots.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for UCH-L1/PGP9.5 Antibody [Alexa Fluor™ Plus 555]

• EC 3.4.19.12
• EC 6.-
• Neuron cytoplasmic protein 9.5
• PARK5
• PGP 9.5
• PGP9.5
• PGP9.5Uch-L1
• PGP95
• ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
• ubiquitin carboxyl-terminal hydrolase isozyme L1
• ubiquitin C-terminal hydrolase
• Ubiquitin thioesterase L1
• UCHL1
• UCH-L1

Background

Deubiquitination is a critical regulatory process in the ubiquitin-proteasome pathway (1). Ubiquitin C-terminal hydrolases (UCHs) are a family of cysteine proteases that catalyze the hydrolysis of a peptide bond at the C-terminal glycine of ubiquitin. Members of the UCH family have been implicated in a number of human diseases, including neurodegenerative diseases and cancers (2). Mutations of the UCH-L1 gene and alterations of the protein activity have been found to be associated with several neurodegenerative disorders, including Parkinson’s, Huntington’s and Alzheimer’s diseases (3). It is also implicated in cancer tumorigenesis, including lung, breast, liver, kidney, colorectal and ovarian cancers (4‑8). UCH-L1 is thought to be a tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors.

1. Wing, S. (2003) Int. J. Biochem. Cell Biol. 35:590.
2. Ventii, KH and Wilkinson, KD (2008) Biochem. J. 414:161.
3. Gong, B. and Leznik, E. (2007) Drug News Perspect. 20:365.
4. Kim, H. et al. (2009) Oncogene 28:117.
5. Wang, W. et al. (2008) Int. J. Oncol. 33:1037.
6. Yu, J. et al. (2008) Hepatology 48:508.
7. Kagara, I. et al. (2008) J. Urol. 180:343.
8. Okochi-Takada, E. et al. (2006) Int. J. Cancer 119:1338.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.